Description
What it is
Dual GLP-1 / glucagon receptor agonist (BI 456906). Investigational for obesity and MASH.
Mechanism
Survodutide engages GLP-1 and glucagon receptors, with proposed effects on hepatic fat reduction alongside body-weight control.
Specifications
- Peptide content: 15mg / vial
- Form: Lyophilized powder
- Storage: 2–8°C, protected from light
For laboratory research only. Not for human or veterinary use.
